ArrayExpress Uploader03731RPMI-1640, 10% FBSKMM-1RPMI-1640, 10% FBSKMS-11RPMI-1640, 20% FBSKMS-12-PERPMI-1640, 20% FBSKMS-12-BMIMDM, 10% FBSlp-1RPMI-1640, 10% FBSMM1SRPMI-1640, 10% FBSMOLP-2RPMI-1640, 20% FBSMOLP-8RPMI-1640, 20% FBS, 2 mM L-glutamine, 1 mM sodium-pyrovateNCI-H929RPMI-1640, 10% FBSOPM-2RPMI-1640, 10% FBSRPMI-8226RPMI-1640, 10% FBS, 5 μM melphalan was added once a weekRPMI-8226 LR5RPMI-1640, 10% FBSU-266RPMI-1640, 20% FBSAMO-1RPMI-1640, 20% FBSDBRPMI-1640, 10% FBSHTRPMI-1640, 10% FBSOCI-Ly7RPMI-1640, 10% FBSSU-DHL-4arrayexpress_sid4A predictive gene list for response to high dose melphalan therapy in patients diagnosed with multiple myeloma is generated by combining...21559449E-GEOD-22759/profile/8773/arrayexpressuploader218celllinemedianmultiple myelomamyelomaDec.12, 2014Falseexpression-data-from-cell-lines-originating-from-pE-GEOD-22759_A-AFFY-44Expression data from cell lines originating from patients with multiple myeloma, plasmacytoma and diffuse large B-cell lymphomaSep.15, 2014A predictive gene list for response to high dose melphalan therapy in patients diagnosed with multiple myeloma is generated by combining results from dose response experiments and microarray data using a B-cell line panel and the introduction of multivariate regression techniques. 18 malignant B-cell lines were analyzed by gene expression microarrays and screened for melphalan median dose dependent growth inhibition. Results are used to build a predictive gene list for response to high dose melphalan therapy in multiple myeloma.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22759humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22759/samples/